CBIO - Gyre Therapeutics Inc
Close
0.51
0.510 100.000%
Share volume: 0
Last Updated: Mon 30 Oct 2023 08:00:00 PM CET
Pharmaceutical Preparation Manufacturing :
2.75%
PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
View ratios
| Fiscal Date | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | |
|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | |
| Report Date | 2022-05-09 | 2022-08-15 | 2022-11-14 | 2023-03-30 | |
| Total revenue | 794.000 K | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 798.000 K | 0.000 | 0.000 | 0.000 | |
| Gross profit | -4.000 K | 0.000 | 0.000 | 0.000 | |
| 100.00% | nan% | nan% | |||
| Operating expenses | 14.697 M | 5.715 M | 5.166 M | 4.825 M | |
| Selling general and admin | 4.994 M | 3.844 M | 4.363 M | 4.165 M | |
| Research and development | 9.703 M | 1.871 M | 803.000 K | 660.000 K | |
| Total expenses | 15.495 M | 5.715 M | 5.166 M | 4.825 M | |
| -63.12% | -9.61% | -6.60% | |||
| Operating income | -14.701 M | -5.715 M | -5.166 M | -4.825 M | |
| Ebit | -14.701 M | -5.715 M | -5.166 M | -4.825 M | |
| Pretax income | -14.536 M | 51.632 M | -4.884 M | -40.106 M | |
| -455.20% | -109.46% | 721.17% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 348.000 K | |
| Net income basic | -14.536 M | 51.632 M | -4.884 M | -40.454 M | |
| 455.20% | -109.46% | -728.30% | |||
| Net income | -14.536 M | 51.632 M | -4.884 M | -40.454 M | |
| 455.20% | -109.46% | -728.30% |